AZN•benzinga•
Interim Analysis Of DESTINY-Breast 09 Phase III Trial Showd ENHERTU Plus Ertuzumab Demonstrated Statistically Significant And Clinically Meaningful Improvement In Progression-free Survival vs Taxane, Trastuzumab And Pertuzumab As 1st-Line Treatment For P
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 21, 2025 by benzinga